Cargando…
Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole
Delusions, hallucinations and other psychotic symptoms can accompany a number of conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medications for the treatment of psychosis in both acute and chronic conditions. Those conditions include schizophrenia, bipolar d...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846120/ https://www.ncbi.nlm.nih.gov/pubmed/20361061 |
_version_ | 1782179456166658048 |
---|---|
author | Kohen, Izchak Lester, Paula E Lam, Sum |
author_facet | Kohen, Izchak Lester, Paula E Lam, Sum |
author_sort | Kohen, Izchak |
collection | PubMed |
description | Delusions, hallucinations and other psychotic symptoms can accompany a number of conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medications for the treatment of psychosis in both acute and chronic conditions. Those conditions include schizophrenia, bipolar disorder, depression and dementia. Elderly patients are at an increased risk of adverse events from antipsychotic medications because of age-related pharmacodynamic and pharmacokinetic changes as well as polypharmacy. Drug selection should be individualized to the patient’s previous history of antipsychotic use, current medical conditions, potential drug interactions, and potential side effects of the antipsychotic. Specifically, metabolic side effects should be closely monitored in this population. This paper provides a review of aripiprazole, a newer second generation antipsychotic agent, for its use in a variety of psychiatric disorders in the elderly including schizophrenia, bipolar disorder, dementia, Parkinson’s disease and depression. We will review the pharmacokinetics and pharmacodynamics of aripiprazole as well as dosing, diagnostic indications, efficacy studies, and tolerability including its metabolic profile. We will also detail patient focused perspectives including quality of life, patient satisfaction and adherence. |
format | Text |
id | pubmed-2846120 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2010 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-28461202010-04-01 Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole Kohen, Izchak Lester, Paula E Lam, Sum Neuropsychiatr Dis Treat Expert Opinion Delusions, hallucinations and other psychotic symptoms can accompany a number of conditions in late life. As such, elderly patients are commonly prescribed antipsychotic medications for the treatment of psychosis in both acute and chronic conditions. Those conditions include schizophrenia, bipolar disorder, depression and dementia. Elderly patients are at an increased risk of adverse events from antipsychotic medications because of age-related pharmacodynamic and pharmacokinetic changes as well as polypharmacy. Drug selection should be individualized to the patient’s previous history of antipsychotic use, current medical conditions, potential drug interactions, and potential side effects of the antipsychotic. Specifically, metabolic side effects should be closely monitored in this population. This paper provides a review of aripiprazole, a newer second generation antipsychotic agent, for its use in a variety of psychiatric disorders in the elderly including schizophrenia, bipolar disorder, dementia, Parkinson’s disease and depression. We will review the pharmacokinetics and pharmacodynamics of aripiprazole as well as dosing, diagnostic indications, efficacy studies, and tolerability including its metabolic profile. We will also detail patient focused perspectives including quality of life, patient satisfaction and adherence. Dove Medical Press 2010 2010-03-24 /pmc/articles/PMC2846120/ /pubmed/20361061 Text en © 2010 Kohen et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Expert Opinion Kohen, Izchak Lester, Paula E Lam, Sum Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole |
title | Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole |
title_full | Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole |
title_fullStr | Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole |
title_full_unstemmed | Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole |
title_short | Antipsychotic treatments for the elderly: efficacy and safety of aripiprazole |
title_sort | antipsychotic treatments for the elderly: efficacy and safety of aripiprazole |
topic | Expert Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846120/ https://www.ncbi.nlm.nih.gov/pubmed/20361061 |
work_keys_str_mv | AT kohenizchak antipsychotictreatmentsfortheelderlyefficacyandsafetyofaripiprazole AT lesterpaulae antipsychotictreatmentsfortheelderlyefficacyandsafetyofaripiprazole AT lamsum antipsychotictreatmentsfortheelderlyefficacyandsafetyofaripiprazole |